Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16387
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChia, Puey Ling-
dc.contributor.authorRussell, Prudence A-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorJohn, Thomas-
dc.date2016-10-04-
dc.date.accessioned2016-10-25T03:35:52Z-
dc.date.available2016-10-25T03:35:52Z-
dc.date.issued2016-10-12-
dc.identifier.citationExpert Review of Anticancer Therapy 2016; online first: 4 Octoberen_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16387-
dc.description.abstractIntroduction: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated with a poor prognosis. Areas covered: MMs induce a strong inflammatory response that is also associated with neoangiogenesis and activation of proangiogenic factors. Given this, several anti-angiogenic agents have been trialled in a variety of malignancies including mesothelioma. Herein we summarise the role of angiogenesis in MM and the current available data targeting these pathways. Expert commentary: The addition of bevacizumab to cisplatin/pemetrexed chemotherapy is currently a therapeutic option with a proven 2.7 month overall survival benefit in fit patients less than 75. Other antiangiogenics such as nintedinib show early promise, although the Phase III trial results are eagerly awaited before this therapy enters treatment paradigms. Beyond this, it is likely that combinations of antiangiogenics with immunotherapies will be investigated in future studies.en_US
dc.subjectAngiogenesisen_US
dc.subjectMesotheliomaen_US
dc.subjectAnti-angiogenic agentsen_US
dc.subjectTumour microenvironmenten_US
dc.subjectVascular endothelial growth factoren_US
dc.titleTargeting the vasculature: anti-angiogenic agents for malignant mesotheliomaen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleExpert Review of Anticancer Therapyen_US
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia-Newton John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Anatomical Pathology, St Vincent's Hospital, the University of Melbourne, Fitzroy, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationFaculty of Medicine, The University of Melbourne, Melbourne, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27696931en_US
dc.identifier.doi10.1080/14737140.2016.1244008en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-6656-295Xen_US
dc.type.austinJournal Articleen_US
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 1, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.